News
DRMA
1.680
+25.37%
0.340
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $4
Benzinga · 8h ago
--Maxim Adjusts Price Target on Dermata Therapeutics to $4 From $16, Keeps Buy Rating
--Maxim Adjusts Price Target on Dermata Therapeutics to $4 From $16, Keeps Buy Rating
MT Newswires · 11h ago
89bio, SCYNEXIS top healthcare gainers; NuCana, Nutex among losers
Seeking Alpha · 1d ago
Petco Health and Wellness, Luminar Technologies, Akero Therapeutics among premarket losers' pack
Seeking Alpha · 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 2d ago
ALT, SOUN and BBAI among mid-day movers
Seeking Alpha · 2d ago
Dermata Therapeutics Closes $5 Million Stock and Warrants Offering; Shares Rise
Dermata Therapeutics Closes $5 Million Stock and Warrants Offering; Shares Rise
MT Newswires · 2d ago
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga · 6d ago
Dermata Therapeutics Filed Certificate Of Amendment To Co's Amended, Restated Certificate Of Incorporation, As Amended, With State Of Delaware; Amendment Will Effect, On March 14, A 1-for-16 Reverse Stock Of Co's Issued, Outstanding Shares Of Common Stock
Benzinga · 03/13 17:27
Dermata launches stock and warrant offering
Seeking Alpha · 03/02 12:03
Maxim Group Sticks to Its Buy Rating for Dermata Therapeutics (DRMA)
TipRanks · 02/23 19:25
BRIEF-Dermata Therapeutics Inc - End Of Phase 2 Meeting With FDA For Dmt310 For Moderate-To-Severe Acne Expected In 2Q 2023
Reuters · 02/21 22:23
Dermata Therapeutics GAAP EPS of -$0.87 beats by $0.03
Seeking Alpha · 02/21 21:58
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 02/16 21:31
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/17 21:31
Why Geron Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/05 13:01
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 01/03 18:39
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 01/03 13:05
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Benzinga · 01/03 12:55
More
Webull provides a variety of real-time DRMA stock news. You can receive the latest news about Dermata Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About DRMA
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its product candidates include DMT310 and DMT410. Its lead product candidate DMT310 is intended to utilize its Spongilla technology for the once-weekly treatment of a variety of skin diseases with its initial focus being on the treatment of acne vulgaris. DMT310 completed a Phase Ib proof of concept (POC) trial in psoriasis. Its second product candidate utilizing its Spongilla technology is its combination treatment, DMT410. DMT410 is intended to consist of one treatment of its sponge powder followed by one topical application of botulinum toxin for delivery into the dermis. DMT410 Phase I POC trial of DMT410 for the treatment of multiple aesthetic skin conditions, including reduction of pore size, sebum production, and fine lines.